Effect of Xihuang Capsules in adjuvant treatment of colon cancer patients with liver metastases and on IL-17 and IL-6 in serum of patients / 中草药

ABSTRACT

To investigate the effect and side effects of Xelox program combined with Xihuang Capsules on therapy to liver metastasis after resection of colon cancer and its impacts on IL-17 and IL-6 levels in serum of patients. Patients with liver metastasis of colorectal cancer after operation (120 cases) were randomly divided into two groups, namely the experimental group and the control group, 60 cases in each group. The patients in the control group were treated with Xerox program, while the patients in the experimental group were treated with the Xelox program and Xihuang Capsules. Twenty healthy cases were controlled. ELISA was used to detect the changes of serum IL-6 and IL-17 of the patients in the experimental group and the control group. Detecting the toxic reaction and hematological tumor makers of the 120 cases after treatment and taking 20 healthy people as control. The effective rates in the experimental group and the control group were 56.67% and 35.59% respectively, which showed the higher in the experimental group than the control group with the significant difference between the two (P < 0.05). The part of toxic reaction and hematological tumor makers in the experimental group were lower than those in the control group, which had significant difference. The levels of IL-17 and IL-6 in serum of the patiente in the experimental group and control group were higher than those in the healthy group (P < 0.05). The levels of IL-17 and IL-6 in the experimental group and control group decreased after the treatment, which the levels of them in the experimental group were more obviously decreased than those in the control group (P < 0.05). Curative efficacy of Xihuang Capsules in adjuvant treatment to colon cancer is reliable, which can reduce chemotherapy part of toxicity and hematological tumor markers, decrease the levels of IL-17 and IL-6, and effectively regulate immune function.